Prophylaxis in von Willebrand disease

Area of Science:

• Hematology
• Internal Medicine
• Pharmacology

Background:

• Von Willebrand disease (VWD) is the most prevalent inherited bleeding disorder.
• VWD classification includes types 1 and 3 (quantitative VWF deficiency) and type 2 (qualitative VWF defect).
• Treatment options for VWD encompass desmopressin (for 70-80% of patients) and factor VIII/VWF concentrates.

Purpose of the Study:

• To review current therapeutic strategies for Von Willebrand disease.
• To evaluate the evidence supporting short-term versus long-term prophylaxis in VWD patients.
• To identify the need for further research in long-term VWD management.

Main Methods:

• Literature review of existing studies on VWD treatment and prophylaxis.
• Analysis of data concerning the efficacy and safety of desmopressin and VWF concentrates.
• Assessment of evidence for short-term and long-term prophylactic regimens in VWD.

Main Results:

• Short-term prophylaxis in VWD demonstrates consistent safety and efficacy.
• Limited evidence exists for the long-term prophylaxis of VWD.
• Preliminary findings on long-term VWD prophylaxis are promising but require validation.

Conclusions:

• Desmopressin and VWF concentrates are key treatments for Von Willebrand disease.
• Established short-term prophylaxis contrasts with the need for more data on long-term VWD prophylaxis.
• Large prospective studies are essential to validate the role of long-term prophylaxis in VWD management.